BioLineRx Ltd. Files Form 6-K Announcing Press Release
Ticker: BLRX · Form: 6-K · Filed: May 24, 2024 · CIK: 1498403
| Field | Detail |
|---|---|
| Company | Biolinerx LTD. (BLRX) |
| Form Type | 6-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
BioLineRx dropped a 6-K on 5/24, likely with news. Check the exhibits.
AI Summary
On May 24, 2024, BioLineRx Ltd. issued a press release filed as Exhibit 1 to this Form 6-K. The filing itself does not contain substantive details beyond the announcement of this press release.
Why It Matters
This filing indicates that BioLineRx Ltd. has made a new announcement to the public, which may contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release and does not contain new financial or operational information that would immediately impact risk.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- May 24, 2024 (date) — Date of press release issuance
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report that BioLineRx Ltd. issued a press release on May 24, 2024, which is included as Exhibit 1.
When was the press release issued by BioLineRx Ltd.?
The press release was issued on May 24, 2024.
What is the Commission file number for BioLineRx Ltd.?
The Commission file number for BioLineRx Ltd. is 001-35223.
Where is BioLineRx Ltd. located?
BioLineRx Ltd. is located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Does BioLineRx Ltd. file annual reports under Form 20-F or Form 40-F?
BioLineRx Ltd. files annual reports under Form 20-F.
Filing Stats: 150 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-05-24 07:05:21
Filing Documents
- zk2431506.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 20KB
- image00001.jpg (GRAPHIC) — 403KB
- 0001178913-24-001827.txt ( ) — 585KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On May 24, 2024, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: May 24, 2024